Naari Pharma Private Limited, a Bengaluru-based vertically integrated women’s health pharma business focused on hormones, announced that it has entered into a definitive asset purchase agreement to acquire 10 Abbreviated New Drug Applications (ANDAs) for the U.S. market from Intas Pharmaceuticals Ltd.
The portfolio acquired comprises eight U.S. FDA approved ANDAs and two products pending approval. It includes generic products in female hormones which will be manufactured at Naari’s dedicated female hormone facility in India and commercialized over the next 24 months.
Naari is a vertically integrated global women’s health pharmaceutical business focused on hormones and has development and manufacturing capabilities across intermediates, active pharmaceutical ingredients, and finished dosage forms (FDFs).
Commenting on the acquisition, Prithi S Kochhar, Co-Founder and CEO of Naari, said: “This is great news for us and another milestone in our journey towards becoming a leading global player in the field of women’s health. This is an important step towards developing our U.S. portfolio. With these newly acquired ANDAs we now have market access of $900 million as per IQVIA data.”
Earlier in 2019, Naari acquired three ANDAs from OC Pharm in the U.S. and in February 2020 the company announced that it had received an equity investment of $17.5 million from Ascent Capital, a leading India-focused growth capital provider.
Prithi S Kochhar continued: “Our journey into the U.S. market is well charted and we expect sales and a positive growth trajectory beginning in the next 12 months. We now have all the key enablers in place towards achieving our revenue target of $100 million in the next 4-5 years, which should make us one of the top women’s health companies in the world and enable us to continue providing vital products to support women’s health across the globe.”
Intas is a leading multinational pharmaceutical formulation development, manufacturing and marketing company with a presence in more than 85 countries worldwide. Estimated to be worth $4.25 billion, Intas is one of the most valued private pharmaceutical companies in India.
Naari Pharma is a vertically integrated women’s health pharma business focused on hormones. The company has a comprehensive FDF product portfolio with a presence in over 50 countries and a shift towards high-value formulations and regulated markets.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.